Insights › Medicine & pharma › November 17, 2026
Medicine & pharma · Pipeline & development

Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

PR Newswire (Health) Published: Results

- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.